Literature DB >> 10683339

Distinct transcriptional and functional properties of the R transactivator gene orf50 of the transforming herpesvirus saimiri strain C488.

M Thurau1, A Whitehouse, S Wittmann, D Meredith, H Fickenscher.   

Abstract

The transformation-associated region of herpesvirus saimiri strains is variable, whereas other parts of the virus genome are highly conserved. However, we observed considerable interstrain sequence divergence of the early viral regulatory orf50 gene, which encodes the R transactivator, a homolog of Epstein-Barr virus BRLF1. The orf50 gene of strain C488 was transcribed at low abundance during lytic infection, whereas antisense transcripts were simultaneously expressed at high levels. A spliced variant, orf50a, was detectable by RT-PCR and RNase protection assays in stimulated C488-transformed, nonpermissive human T cells. In contrast to strain A11, the short, unspliced orf50b form of C488 displayed complete transactivation capability on the orf6 and orf57 promoters. In summary, there are unexpected structural and functional differences between the orf50 genes of herpesvirus saimiri strains, which differ in their capability to transform human T lymphocytes. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10683339     DOI: 10.1006/viro.1999.0167

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  9 in total

1.  Octamer-binding sequence is a key element for the autoregulation of Kaposi's sarcoma-associated herpesvirus ORF50/Lyta gene expression.

Authors:  S Sakakibara; K Ueda; J Chen; T Okuno; K Yamanishi
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) replication and transcription factor activates the K9 (vIRF) gene through two distinct cis elements by a non-DNA-binding mechanism.

Authors:  Keiji Ueda; Kayo Ishikawa; Ken Nishimura; Shuhei Sakakibara; Eunju Do; Koichi Yamanishi
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

Review 3.  Herpesvirus saimiri.

Authors:  H Fickenscher; B Fleckenstein
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

4.  Open reading frame 50 protein of Kaposi's sarcoma-associated herpesvirus directly activates the viral PAN and K12 genes by binding to related response elements.

Authors:  Pey-Jium Chang; Duane Shedd; Lyn Gradoville; Myung-Sam Cho; Lee-Wen Chen; Jimmy Chang; George Miller
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

5.  Herpesvirus saimiri open reading frame 50 (Rta) protein reactivates the lytic replication cycle in a persistently infected A549 cell line.

Authors:  D J Goodwin; M S Walters; P G Smith; M Thurau; H Fickenscher; A Whitehouse
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

6.  Genome-wide histone acetylation profiling of Herpesvirus saimiri in human T cells upon induction with a histone deacetylase inhibitor.

Authors:  Barbara Alberter; Benjamin Vogel; Doris Lengenfelder; Florian Full; Armin Ensser
Journal:  J Virol       Date:  2011-03-23       Impact factor: 5.103

7.  The latency-associated nuclear antigen homolog of herpesvirus saimiri inhibits lytic virus replication.

Authors:  Alexandra Schäfer; Doris Lengenfelder; Christian Grillhösl; Carsten Wieser; Bernhard Fleckenstein; Armin Ensser
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

8.  Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 transcriptional activator Rta is an oligomeric DNA-binding protein that interacts with tandem arrays of phased A/T-trinucleotide motifs.

Authors:  Wei Liao; Yong Tang; Yu-Liang Kuo; Bao-Ying Liu; Chi-Jie Xu; Chou-Zen Giam
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

9.  ORF73 of herpesvirus Saimiri strain C488 tethers the viral genome to metaphase chromosomes and binds to cis-acting DNA sequences in the terminal repeats.

Authors:  Subhash C Verma; Erle S Robertson
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.